Search Results - "Janni, W"

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer by Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., Yap, Y.S., Sonke, G.S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K.L., Winer, E.P., Janni, W., Verma, S., Conte, P., Arteaga, C.L., Cameron, D.A., Mondal, S., Su, F., Miller, M., Elmeliegy, M., Germa, C., O’Shaughnessy, J.

“…The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line…”
Get full text

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials by Bradley, Rosie, Braybrooke, Jeremy, Gray, Richard, Hills, Robert, Liu, Zulian, Peto, Richard, Davies, Lucy, Dodwell, David, McGale, Paul, Pan, Hongchao, Taylor, Carolyn, Anderson, Stewart, Gelber, Richard, Gianni, Luca, Jacot, William, Joensuu, Heikki, Moreno-Aspitia, Alvaro, Piccart, Martine, Press, Michael, Romond, Edward, Slamon, Dennis, Suman, Vera, Berry, Richard, Boddington, Clare, Clarke, Mike, Davies, Christina, Duane, Fran, Evans, Vaughan, Gay, Jo, Gettins, Lucy, Godwin, Jon, James, Sam, Liu, Hui, MacKinnon, Elizabeth, Mannu, Gurdeep, McHugh, Theresa, Morris, Philip, Read, Simon, Straiton, Ewan, Wang, Yaochen, Crown, John, de Azambuja, Evandro, Delaloge, Suzette, Fung, Helena, Geyer, Charles, Spielmann, Marc, Valagussa, Pinuccia, Albain, Kathy, Arriagada, Rodrigo, Bartlett, John, Bergsten-Nordström, Elizabeth, Bliss, Judith, Brain, Etienne, Carey, Lisa, Coleman, Robert, Cuzick, Jack, Davidson, Nancy, Del Mastro, Lucia, Di Leo, Angelo, Dignam, James, Dowsett, Mitch, Ejlertsen, Bent, Francis, Prue, Gnant, Michael, Goetz, Matthew, Goodwin, Pam, Halpin-Murphy, Pat, Hayes, Dan, Hill, Catherine, Jagsi, Reshma, Janni, Wolfgang, Loibl, Sibylle, Mamounas, Eleftherios P, Martín, Miguel, Mukai, Hirofumi, Nekljudova, Valentina, Norton, Larry, Ohashi, Yasuo, Pierce, Lori, Poortmans, Philip, Raina, Vinod, Rea, Daniel, Regan, Meredith, Robertson, John, Rutgers, Emiel, Spanic, Tanja, Sparano, Joseph, Steger, Guenther, Tang, Gong, Toi, Masakazu, Tutt, Andrew, Viale, Giuseppe, Wang, Xiang, Whelan, Tim, Wilcken, Nicholas, Wolmark, Norman, Cameron, David, Bergh, Jonas, Pritchard, Kathleen I, Swain, Sandra M

“…Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer…”
Get full text

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Loibl, S, André, F, Bachelot, T, Barrios, C H, Bergh, J, Burstein, H J, Cardoso, M J, Carey, L A, Dawood, S, Del Mastro, L, Denkert, C, Fallenberg, E M, Francis, P A, Gamal-Eldin, H, Gelmon, K, Geyer, C E, Gnant, M, Guarneri, V, Gupta, S, Kim, S B, Krug, D, Martin, M, Meattini, I, Morrow, M, Janni, W, Paluch-Shimon, S, Partridge, A, Poortmans, P, Pusztai, L, Regan, M M, Sparano, J, Spanic, T, Swain, S, Tjulandin, S, Toi, M, Trapani, D, Tutt, A, Xu, B, Curigliano, G, Harbeck, N

Get more information

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial by Ignatiadis, M., Litière, S., Rothe, F., Riethdorf, S., Proudhon, C., Fehm, T., Aalders, K., Forstbauer, H., Fasching, P.A., Brain, E., Vuylsteke, P., Guardiola, E., Lorenz, R., Pantel, K., Tryfonidis, K., Janni, W., Piccart, M., Sotiriou, C., Rack, B., Pierga, J.-Y.

“…Trastuzumab improves the outcome of women with HER2 positive breast cancer. We aimed to assess whether trastuzumab decreases the detection rate of circulating…”
Get full text

The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial by Jaeger, B A S, Neugebauer, J, Andergassen, U, Melcher, C, Schochter, F, Mouarrawy, D, Ziemendorff, G, Clemens, M, V Abel, E, Heinrich, G, Schueller, K, Schneeweiss, A, Fasching, P, Beckmann, M W, Scholz, Ch, Friedl, T W P, Friese, K, Pantel, K, Fehm, T, Janni, W, Rack, B

“…HER2 is one of the predominant therapeutic targets in breast cancer. The metastatic selection process may lead to discrepancies between the HER2 status of the…”
Get full text

Replies - Letter to the Editor - “Effect of a comprehensive lifestyle intervention program on body weight and health behavior in women with breast cancer: Results from a randomized controlled trial” by Hauner, D., Günther, J., Schederecker, F., Donik, L., Meyer, D., Hermsdörfer, J., Friedl, T.W.P., Rack, B., Beckmann, M.W., Janni, W., Hauner, H.

Get full text

EP02.15: Practising fetal echocardiography effectively by combining a conventional learning method and the Scanbooster Ultrasound Sim app by Hartmann, T.J., Friebe‐Hoffmann, U., Hartmann, J.B., Grab, D., Lato, C., Janni, W., Lato, K.

Get full text

EP02.13: Evaluation of ultrasound training with 3D face recognition and artificial intelligence in real time by Hartmann, T.J., Friebe‐Hoffmann, U., Hartmann, J.B., Grab, D., Lato, C., Janni, W., Lato, K.

Get full text

Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients by Wolters, R., Wöckel, A., Janni, W., Novopashenny, I., Ebner, F., Kreienberg, R., Wischnewsky, M., Schwentner, L.

“…Multifocal (MF) and multicentric (MC) breast cancers have been comprehensively studied, and their outcomes have been compared with unifocal (UF) tumors. We…”
Get full text

VP34.17: Practicing fetal echocardiography with the Scanbooster ultrasound simulator app on smartphone and tablet by Hartmann, T.J., Friebe‐Hoffmann, U., Lato, C., Friedl, T., Janni, W., Lato, K.

Get full text

OC10.08: Comparing a new form of ultrasound simulation on smartphone and tablet to a conventional learning method by Hartmann, T.J., Friebe‐Hoffmann, U., Lato, C., Friedl, T., Janni, W., Lato, K.

Get full text

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer by Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., Yap, Y.S., Sonke, G.S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K.L., Winer, E.P., Janni, W., Verma, S., Conte, P., Arteaga, C.L., Cameron, D.A., Mondal, S., Su, F., Miller, M., Elmeliegy, M., Germa, C., O’Shaughnessy, J.

Get full text

Predictors of the course of quality of life during therapy in women with primary breast cancer by Wöckel, Achim, Schwentner, L., Krockenberger, M., Kreienberg, R., Janni, W., Wischnewsky, M., Thorsten, Kühn, Felix, Flock, Riccardo, Felberbaum, Blettner, M., Singer, S.

“…Purpose Multimodal therapies affect the quality of life (QoL) of patients with primary breast cancer (PBC). The objectives of this prospective study were to…”
Get full text

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto) by von Minckwitz, G., Fasching, P.A., Schrader, I., Kittel, K., Huober, J., Solbach, C., Jackisch, C., Blohmer, J.U., Nekljudova, V., Gerber, B., Groh, U., Villena, C., Liedtke, B., Kittel, K., Mau, C., Potenberg, J., Schilling, J., Just, M., Bückner, U., Doering, G., Feidicker, S., Krabisch, P., Augustin, D., Nestle-Krämling, C., Rezai, M., Höß, C., Terhaag, J., Fasching, P., Staib, P., Aktas, B., Kühn, T., Khandan, F., Möbus, V., Solbach, C., Tesch, H., Stickeler, E., Heinrich, G., Wagner, H., Abdallah, A., Dewitz, T., Emons, G., Belau, A., Rethwisch, V., Lantzsch, T., Müller, V., Holms, F., Müller, T., Deuker, J.-U., Solomayer, E., Runnebaum, I., Link, H., Conrad, B., Feisel-Schwickardi, G., Steinmetz, T., Langanke, D., Ober, A., Fischer, D., Kohls, A., Weikel, W., Bischoff, J., Freese, K., Wiest, W., Sütterlin, M., Dietrich, M., Grießhammer, M., Burgmann, D.-M., Hanusch, C., Rack, B., Salat, C., Sattler, D., Tio, J., Christensen, B., Burkamp, U., Köhne, C.-H., Meinerz, W., Graßhoff, S.-T., Decker, T., Thalmann, I., Sallmann, A., Beck, T., Reimer, T., Bartzke, G., Deryal, M., Weigel, M., Huober, J., Steffens, C.-C., Lemster, S., Stefek, A., Ruhland, F., Hofmann, M., Schuster, J., Clemens, M., Fehm, T., Janni, W., Latos, K., Bauer, W., Roßmann, A., Bauer, L., Hoffmann, G., Schlag, R.

“…The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline–taxane–based neoadjuvant chemotherapy increases pathological complete…”
Get full text

Financial difficulties in breast cancer survivors with and without migration background in Germany—results from the prospective multicentre cohort study BRENDA II by Riccetti, N., Felberbaum, R., Flock, F., Kühn, T., Leinert, E., Schwentner, L., Singer, S., Taylor, K., Wöckel, A., Janni, W.

“…Purpose We aimed to explore the trajectory of financial difficulties among breast cancer survivors in the German health system and its association with…”
Get full text

Prognostic factors for and pattern of lymph-node involvement in patients with operable cervical cancer by Widschwendter, P., Janni, W., Scholz, C., De Gregorio, A., De Gregorio, N., Friedl, T W P

“…Purpose Lymph node metastases significantly worsen the prognosis in cervical carcinoma. Risk factors—pathological and patient related—could select patients at…”
Get full text

The impact of adjuvant radiotherapy on the survival of primary breast cancer patients: a retrospective multicenter cohort study of 8935 subjects by Wöckel, A., Wolters, R., Wiegel, T., Novopashenny, I., Janni, W., Kreienberg, R., Wischnewsky, M., Schwentner, L.

“…Radiotherapy (RT) is proven to be an important backbone for adjuvant therapy in randomized, controlled trials, but it is unclear if these effects are provable…”
Get full text

Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry by Frevert, M. L., Dannehl, D., Jansen, L., Hermann, S., Schäffler, H., Huwer, S., Janni, W., Juhasz-Böss, I., Hartkopf, A. D., Taran, F.-A.

“…Background Following the positive iDFS and OS results of the phase III clinical trials monarchE, NATALEE and OlympiA, new oral anticancer agents (the CDK4/6…”
Get full text

Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer by Scholz, Christoph, Andergassen, U., Hepp, P., Schindlbeck, C., Friedl, Thomas W. P., Harbeck, N., Kiechle, M., Sommer, H., Hauner, H., Friese, K., Rack, B., Janni, W.

“…Obese breast cancer patients have a higher risk of lymph node metastasis and a poorer prognosis compared to patients with normal weight. For obese women with…”
Get full text

Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers by Ortmann, O., Blohmer, J.-U., Sibert, N. T., Brucker, S., Janni, W., Wöckel, A., Scharl, A., Dieng, S., Ferencz, J., Inwald, E. C., Wesselmann, S., Kowalski, C.

“…Neoadjuvant chemotherapy (NACT) is frequently used in patients with early breast cancer. Randomized controlled trials have demonstrated similar survival after…”
Get full text